

AVANTI NANOSCIENCES LAUNCHES NEW TARGETED DRUG DELIVERY COMPANY

Baltimore, MD. September, 20, 2007 Avanti NanoSciences, a privately held bionanotechnology company, said it has incubated and launched a new company called Chikujee Therapeutics

Chikujee Therapeutics hopes to commercialize cell specific targeted drug delivery technology originally developed by, and licensed from, Avanti Therapeutics. The company is an emerging specialty bionanotechnology company with expertise in the development of target specific delivery of biopharmaceuticals. The company will employ several platform technologies to manipulate and enhance the performance of drugs. These technologies can be employed with new chemical entities or with generic drugs and can be used with the spectrum of existing drug types ranging from small synthetic molecules to large recombinant macromolecules.

The company's strategy is to use this innovative targeted drug delivery technology to build a portfolio of potentially safer and more effective versions of well-known anti-cancer agents. We believe that our target specific drug development program may lower the risks inherent in developing new drugs because we are customizing our TSDV™ to well defined and widely used radiotherapy and chemotherapy drugs. The company will initially focus the development efforts on applying TSDV™ to two of the fastest growing classes of anticancer drugs, Boron delivery for Boron Neutron Capture Therapy and Methotrexate delivery for Chemotherapy.

Arkesh Mehta, the current CEO of Avanti Therapeutics will serve as the Chairman of the Board. Dr. Mehta's background is in early-stage biotechnology companies, both as a scientist and a business development executive. He also worked in management positions at BIO and LGA Inc. Working with angel investors and venture capital groups, the company intends to recruit top management and scientific staff to maximize investor returns..

Baltimore-based Avanti Therapeutics said in the announcement that Chikujee Therapeutics is the third member of its portfolio of early-stage biotech companies. Their first company, AT-GC BioPharm was acquired by a group of Investors led by Cosmographics Pvt. Ltd. in July 2006.

About Avanti NanoSciences:

Avanti NanoSciences is a privately held company developing novel technologies for the rapid detection of pathogens. The Company's technology is expected to have broad applications in food testing, animal health, and human health care, including drug

discovery and development and disease diagnosis. Avanti NanoSciences is developing PathFinder™ technology platform, a family of next generation, early warning detection devices providing a real-time method for pathogen detection, identification and monitoring.

Avanti NanoScience's patent-pending NanoBindi technology is the basis for an open and ultra sensitive solution which can detect the presence of pathogens including food pathogens, and other weaponized bio-agents. The elegance of the technology provides for a marked improvement in price/performance over current solutions and a drastic reduction in entry price which creates new market opportunities for providing first level protection for food security, water systems, consumer products and Homeland Security. Avanti Nanosciences's initial focus is to provide smart detection capabilities for detection and monitoring of consumer food supply.

Additional information is available at www.anano.at-gc.com and www.chikujee.at-gc.com

For further details related to our capabilities please contact:

Media Relations

Avanti NanoSciences

7720, Bel Air Road, Suite 250

Baltimore, MD 21236

www.analytics.at-gc.com

(301) 540-5474 (Tel.)

(270) 447- 4777(FAX)